Insurers Dropping Top Valeant (VRX) Drugs - Wells Fargo's Maris
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Valeant (VRX) Formulary Changes Were Already Anticipated by Company - Cantor Fitzgerald
July 28, 2017 10:17 AM EDTCantor Fitzgerald analyst Louise Chen came out to defend Valeant Pharmaceuticals (NYSE: VRX) saying today's concerns that formulary changes could adversely impact VRX's sales for certain products are overdone and formulary changes were already anticipated by VRX. The firm maintained an Overweight rating and... More
